Urogen Pharma Ltd (URGN)

$24.11 -0.20 (-0.82%)
Market Cap 1.18B
Revenue (ttm) 109.79M
Net Income (ttm) -153.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -139.80%
Debt to Equity Ratio -1.16
Volume 585,300
Avg Vol 848,616
Day's Range N/A - N/A
Shares Out 48.68M
Stochastic %K 50%
Beta 1.43
Analysts Strong Sell
Price Target $32.86

Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
chickenboy
chickenboy Apr. 24 at 8:39 PM
$URGN
1 · Reply
chickenboy
chickenboy Apr. 24 at 8:38 PM
$URGN Short interest has decreased to 7.63M from 8.35M. I contacted Vincent today at Urogen and he indicated they will also be giving an update on the 2nd tranche of the loan ($50 million). GLTA.
0 · Reply
chickenboy
chickenboy Apr. 22 at 2:34 PM
$URGN I sold off about 1/2 my shares at 27.25 this morning and have no regrets. All my money is in retirement and nothing else coming in yet so have to be a little conservative and lock in gains (and what gains!!!). GLTA and still
1 · Reply
YungBullHOLLA
YungBullHOLLA Apr. 22 at 2:02 PM
$URGN 27 dolla holla!!
0 · Reply
YungBullHOLLA
YungBullHOLLA Apr. 20 at 6:24 PM
$URGN
1 · Reply
flanker30
flanker30 Apr. 20 at 6:10 PM
$URGN any news here?!
1 · Reply
BioTechHealthX
BioTechHealthX Apr. 19 at 2:40 AM
$URGN UroGen Pharma (NASDAQ:URGN) has moved beyond the risky development stage and into real revenue generation. With rising physician adoption and expanding market access, this oncology-focused biotech could be entering a powerful new growth phase investors are starting to notice. https://biotechhealthx.com/biotech-news/is-it-still-practical-to-invest-in-urogen-pharma-ltd-urgn/
0 · Reply
Quantumup
Quantumup Apr. 17 at 12:24 PM
Cantor reiterated $TYRA at an Overweight rating $URGN $CGON JNJ IBRX Here's what Cantor said in its note: https://x.com/Quantumup1/status/2045115106401431856?s=20
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 16 at 4:19 AM
$URGN UroGen Pharma is no longer just another speculative biotech. With real revenues and growing adoption, URGN stock may be entering a new phase of stability and upside potential investors can’t ignore. https://biotechhealthx.com/biotech-news/is-now-the-best-time-to-acquire-urogen-pharma-urgn-shares/
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 5:57 AM
$ADMA $CRMD $EYPT $URGN $VRDN Looking for high-risk, high-reward biotech stocks? These top 5 microcap biotech companies are positioned for major breakthroughs that could drive significant upside for early investors. https://biotechhealthx.com/biotech-news/top-5-microcap-biotech-stocks-that-could-multiply-your-money-fast/
0 · Reply
Latest News on URGN
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Apr 8, 2026, 8:00 AM EDT - 17 days ago

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

Mar 30, 2026, 8:00 AM EDT - 26 days ago

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2026, 4:10 PM EST - 7 weeks ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 8:00 AM EST - 7 weeks ago

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

Mar 2, 2026, 7:55 AM EST - 7 weeks ago

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

Feb 27, 2026, 8:30 AM EST - 2 months ago

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:05 PM EST - 2 months ago

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

Feb 23, 2026, 8:00 AM EST - 2 months ago

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

Feb 4, 2026, 8:00 AM EST - 2 months ago

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

Jan 5, 2026, 8:00 AM EST - 3 months ago

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 5 months ago

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

Nov 6, 2025, 8:00 AM EST - 6 months ago

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

Nov 6, 2025, 7:58 AM EST - 6 months ago

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 6 months ago

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Oct 30, 2025, 8:00 AM EDT - 6 months ago

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Oct 2, 2025, 8:00 AM EDT - 7 months ago

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

UroGen Pharma to Present at Upcoming Investor Conferences

Aug 21, 2025, 8:00 AM EDT - 8 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 9 months ago

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Aug 5, 2025, 8:00 AM EDT - 9 months ago

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Jul 29, 2025, 8:00 AM EDT - 9 months ago

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

Jul 28, 2025, 8:00 AM EDT - 9 months ago

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 21, 2025, 8:00 AM EDT - 9 months ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 7, 2025, 8:00 AM EDT - 10 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

Jun 16, 2025, 8:17 AM EDT - 11 months ago

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 15, 2025, 10:17 AM EDT - 11 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 12, 2025, 6:04 PM EDT - 11 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 12, 2025, 1:28 PM EDT - 11 months ago

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

US FDA approves Urogen's bladder cancer drug

Jun 12, 2025, 12:48 PM EDT - 11 months ago

US FDA approves Urogen's bladder cancer drug

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

Jun 10, 2025, 8:47 AM EDT - 11 months ago

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

Jun 9, 2025, 1:36 PM EDT - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Jun 8, 2025, 8:18 AM EDT - 11 months ago

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

Jun 5, 2025, 9:31 AM EDT - 11 months ago

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

chickenboy
chickenboy Apr. 24 at 8:39 PM
$URGN
1 · Reply
chickenboy
chickenboy Apr. 24 at 8:38 PM
$URGN Short interest has decreased to 7.63M from 8.35M. I contacted Vincent today at Urogen and he indicated they will also be giving an update on the 2nd tranche of the loan ($50 million). GLTA.
0 · Reply
chickenboy
chickenboy Apr. 22 at 2:34 PM
$URGN I sold off about 1/2 my shares at 27.25 this morning and have no regrets. All my money is in retirement and nothing else coming in yet so have to be a little conservative and lock in gains (and what gains!!!). GLTA and still
1 · Reply
YungBullHOLLA
YungBullHOLLA Apr. 22 at 2:02 PM
$URGN 27 dolla holla!!
0 · Reply
YungBullHOLLA
YungBullHOLLA Apr. 20 at 6:24 PM
$URGN
1 · Reply
flanker30
flanker30 Apr. 20 at 6:10 PM
$URGN any news here?!
1 · Reply
BioTechHealthX
BioTechHealthX Apr. 19 at 2:40 AM
$URGN UroGen Pharma (NASDAQ:URGN) has moved beyond the risky development stage and into real revenue generation. With rising physician adoption and expanding market access, this oncology-focused biotech could be entering a powerful new growth phase investors are starting to notice. https://biotechhealthx.com/biotech-news/is-it-still-practical-to-invest-in-urogen-pharma-ltd-urgn/
0 · Reply
Quantumup
Quantumup Apr. 17 at 12:24 PM
Cantor reiterated $TYRA at an Overweight rating $URGN $CGON JNJ IBRX Here's what Cantor said in its note: https://x.com/Quantumup1/status/2045115106401431856?s=20
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 16 at 4:19 AM
$URGN UroGen Pharma is no longer just another speculative biotech. With real revenues and growing adoption, URGN stock may be entering a new phase of stability and upside potential investors can’t ignore. https://biotechhealthx.com/biotech-news/is-now-the-best-time-to-acquire-urogen-pharma-urgn-shares/
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 5:57 AM
$ADMA $CRMD $EYPT $URGN $VRDN Looking for high-risk, high-reward biotech stocks? These top 5 microcap biotech companies are positioned for major breakthroughs that could drive significant upside for early investors. https://biotechhealthx.com/biotech-news/top-5-microcap-biotech-stocks-that-could-multiply-your-money-fast/
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 2:52 AM
$EYPT $LQDA $OCGN $URGN $VRDN The biotech sector is heating up again. These top 5 best microcap biotech stocks are gaining traction with strong pipelines, upcoming trial results, and serious upside potential investors shouldn’t ignore. https://biotechhealthx.com/biotech-news/top-5-best-microcap-biotech-stocks-that-could-explode-10x-in-2026/
0 · Reply
chickenboy
chickenboy Apr. 10 at 8:37 PM
$URGN Short interest has decrease slightly to 8.35M from 8.63M. Still
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 10 at 7:16 PM
Commercial-stage oncology focused bio share price changes week to date, excluding $TLX because for some reason we cannot get last week's closing price. Seeking Alpha is reporting TLX is also up 15%. Otherwise, $URGN is (quietly) the best performing commercial-stage oncology focused bio this week. We've seen URGN run for no apparent reason 3 times in the last 4 years only to return to an average. This is not investment advice. $IOVA is next after the REPL CRL $AUTL $RIGL round out the last 2.
1 · Reply
chickenboy
chickenboy Apr. 10 at 2:47 PM
$URGN Jefferies decided to get on board with a target of $40. I had hoped to buy more on the cheap ($15) but it's starting to look like that ship has sailed. GLTA.
0 · Reply
notreload_ai
notreload_ai Apr. 10 at 11:16 AM
Analysts see big upside in $URGN , $RAPP , and $MIST , driven by strong drugs, upcoming data, and underestimated market potential. https://notreload.xyz/xy/analysts-issue-buy-ratings-on-urgn-rapp-mist-stocks/
0 · Reply
deweyeggbert
deweyeggbert Apr. 9 at 11:27 PM
$URGN tomorrow will be revealing.
0 · Reply
ap20
ap20 Apr. 9 at 9:14 PM
$URGN Zus trajectory will be much clearer after q1 earnings in about a month. ‘Might think about buying before then or she be gone..
1 · Reply
NasdaqPulse
NasdaqPulse Apr. 9 at 2:16 PM
$URGN - One of the brokers published today a survey among 36 leading urologists in the U.S. regarding their outlook on the future market distribution in NMIBC cancer. 👉Click to view @NasdaqPulse for timely updates amid the volatility. Although the broker does not cover URGN and tries not to mention its name, URGN’s Zusduri clearly dominates the competition. When the doctors were presented with five different drugs, 44% said that Zusduri would be their first choice for treatment. When asked which drug is most economically beneficial for them, 47% answered Zusduri. When asked about Zusduri’s market share, the forecast was around 35%. This survey predicts a very promising future for URGN. Based on consensus estimates, the stock is trading at a P/E multiple of only 2.9x for 2030! We would be buyers here.
1 · Reply
ivocsev
ivocsev Apr. 8 at 11:56 AM
$URGN
0 · Reply
GeniusLoci
GeniusLoci Apr. 1 at 5:44 PM
$URGN Setup (source: ChartMill)
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 2:48 PM
$URGN RSI: 45.77, MACD: -0.6738 Vol: 0.92, MA20: 18.45, MA50: 19.78 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ivocsev
ivocsev Mar. 30 at 4:34 PM
$URGN this had good news pr today, correct?
0 · Reply